Publications by authors named "O Varenne"
Aims: Dual antiplatelet therapy (DAPT) can be shortened up to 1 month in high-bleeding risk (HBR) patients receiving a contemporary biodegradable-polymer sirolimus-eluting stent. We aimed to summarize the evidence on a similar DAPT regimen after biodegradable-polymer everolimus-eluting stent (EES) implantation in patients at HBR.
Methods And Results: We pooled the individual participant data from the available trials evaluating this strategy, namely, the SENIOR and the POEM trials.
Article Synopsis
- Shortening dual-antiplatelet therapy (DAPT) to 1 month after percutaneous coronary intervention (PCI) is effective and safe for high bleeding risk (HBR) patients, regardless of chronic kidney disease (CKD) status.
- A study analyzed data from 3 prospective studies involving 3,286 patients, of whom 43.6% had CKD, comparing outcomes between 1-month and 3-month DAPT.
- Results indicated that both durations had similar rates of death and myocardial infarction after 12 months, with a slight trend for fewer bleeding complications at 1 month compared to 3 months in both CKD and no-CKD groups.
Article Synopsis
- Some doctors suggest giving patients with a high bleeding risk a shorter treatment of medication after getting a special type of heart stent.
- This study looked at how safe and effective 1 month of this medication is compared to 3 months for patients who also had a type of heart problem or not.
- They found that 1-month treatment had the same chance of serious heart issues as the 3-month treatment, but it caused less bleeding after a year.
Coronary artery disease in older patients is more frequently diffuse and complex, and is often treated by percutaneous coronary intervention on top of medical therapy. There are currently no specific recommendations for antiplatelet therapy in patients aged≥75 years. Aspirin remains pivotal, and is still indicated as a long-term treatment after percutaneous coronary intervention.
View Article and Find Full Text PDF